RxDoctor Payments Data

Hunter Edwards, OD

Optometrist · Water Valley, MSNPI 1326613308

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,068 of the $4,204 with a category attached, or 73.0%. 13 manufacturers reported payments, led by Coopervision Inc. at 31.3% of the total. 2025 is the largest year on record at $1,678, more than ten times the $80 reported in 2021. Among optometrist clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,204in general payments, 2019–2025

Across 46 payments — averaging $91.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$1K
  • Lumenis BE Inc$784
  • Alcon$761
  • Carl Zeiss Meditec USA, Inc.$343
  • AbbVie$193
  • Bausch & Lomb Americas Inc.$166
  • plus $641 from 7 others

What the payments were for

  • Speaking & faculty fees$1,00024%
  • Food & beverage$3,06873%
  • Entertainment$1363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,204 in reported general payments places this provider in the 90th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$91,768
Medicare patients
354
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost37$11,269
VyzultaLatanoprostene Bunod22$8,339
CombiganBrimonidine Tartrate/Timolol12$3,532
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,921
Latanoprost240$1,117
Brimonidine Tartrate13$936
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat88$902
Prednisolone Acetate18$713
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha62$610
Dorzolamide Hcl25$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$193$14,80149 claims
Bausch & Lomb Americas Inc.Vyzulta$166$8,33922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Water Valley

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →